All In Biotech

Drug Trial Radar · NCT03623243

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

Exploring the Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi- Center Phase IIIb Study

Last checked: Nov 20, 2026Latest source record: Jun 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

185

Actual

Start

Feb 14, 2019

Primary completion

Jul 6, 2022

Study completion Jul 6, 2022

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess safety and tolerability of patients converting from approved Relapsing Multiple Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.

Conditions

  • Multiple Sclerosis
  • Relapsing Multiple Sclerosis
  • Advancing Multiple Sclerosis

Interventions

  • SiponimodDrug

    Siponimod 2mg tablets taken once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) Related to Study Drug During the Treatment PeriodTime frame: From first dose of study drug up to 30 days after last dose of study drug (up to 7 months)

Locations

55 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Cullman, Alabama

  • Alabama Neurology Associates

    Homewood, Alabama

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    Fresno, California

  • Novartis Investigative Site

    Fullerton, California

  • Novartis Investigative Site

    Irvine, California

  • Novartis Investigative Site

    Colorado Springs, Colorado

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Fort Collins, Colorado

  • Novartis Investigative Site

    Boca Raton, Florida

  • Novartis Investigative Site

    Bradenton, Florida

  • MS & Neuromuscular Center of Excellence

    Clearwater, Florida

  • Novartis Investigative Site

    Maitland, Florida

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Ocala, Florida

  • Novartis Investigative Site

    Oldsmar, Florida

  • Novartis Investigative Site

    Orlando, Florida

  • Novartis Investigative Site

    Ormond Beach, Florida

  • Novartis Investigative Site

    Sarasota, Florida

  • Novartis Investigative Site

    Sunrise, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    Vero Beach, Florida

  • Novartis Investigative Site

    Flossmoor, Illinois

  • Novartis Investigative Site

    Indianapolis, Indiana

  • Novartis Investigative Site

    Lexington, Kentucky

  • Novartis Investigative Site

    Lexington, Kentucky

  • Novartis Investigative Site

    Lexington, Kentucky

  • Novartis Investigative Site

    Rockville, Maryland

  • Novartis Investigative Site

    Clinton Township, Michigan

  • Novartis Investigative Site

    St Louis, Missouri

  • Novartis Investigative Site

    Las Vegas, Nevada

  • Novartis Investigative Site

    Hackensack, New Jersey

  • Novartis Investigative Site

    Asheville, North Carolina

  • Novartis Investigative Site

    Greensboro, North Carolina

  • Novartis Investigative Site

    Raleigh, North Carolina

  • Novartis Investigative Site

    Cincinnati, Ohio

  • Novartis Investigative Site

    Cleveland, Ohio

  • Novartis Investigative Site

    Oklahoma City, Oklahoma

  • Abington Neurological Associates, Ltd

    Abington, Pennsylvania

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.